- Home
- RLGT vs AKBA Comparison
RLGT vs AKBA Comparison
Compare RLGT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLGT
- AKBA
- Stock Information
- Founded
- RLGT 2001
- AKBA 2007
- Country
- RLGT United States
- AKBA United States
- Employees
- RLGT N/A
- AKBA N/A
- Industry
- RLGT Oil Refining/Marketing
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- RLGT Consumer Discretionary
- AKBA Health Care
- Exchange
- RLGT Nasdaq
- AKBA Nasdaq
- Market Cap
- RLGT 287.6M
- AKBA 958.6M
- IPO Year
- RLGT N/A
- AKBA 2014
- Fundamental
- Price
- RLGT $6.13
- AKBA $3.59
- Analyst Decision
- RLGT
- AKBA Strong Buy
- Analyst Count
- RLGT 0
- AKBA 5
- Target Price
- RLGT N/A
- AKBA $6.90
- AVG Volume (30 Days)
- RLGT 206.1K
- AKBA 6.2M
- Earning Date
- RLGT 05-12-2025
- AKBA 08-07-2025
- Dividend Yield
- RLGT N/A
- AKBA N/A
- EPS Growth
- RLGT 173.51
- AKBA N/A
- EPS
- RLGT 0.35
- AKBA N/A
- Revenue
- RLGT $888,148,000.00
- AKBA $184,909,000.00
- Revenue This Year
- RLGT $12.86
- AKBA $26.88
- Revenue Next Year
- RLGT $5.26
- AKBA $44.34
- P/E Ratio
- RLGT $17.73
- AKBA N/A
- Revenue Growth
- RLGT 7.18
- AKBA N/A
- 52 Week Low
- RLGT $5.26
- AKBA $0.91
- 52 Week High
- RLGT $7.94
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- RLGT 54.25
- AKBA 55.38
- Support Level
- RLGT $5.86
- AKBA $3.60
- Resistance Level
- RLGT $6.24
- AKBA $3.76
- Average True Range (ATR)
- RLGT 0.15
- AKBA 0.18
- MACD
- RLGT 0.02
- AKBA -0.05
- Stochastic Oscillator
- RLGT 63.95
- AKBA 15.62
About RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.